November 9, 2010 – In an effort to further promote the utility of PET/CT (positron emission tomography/computed tomography) imaging in assessing the effectiveness of oncology treatments, a new quantification tool is available to support PERCIST (PET response criteria in solid tumors). PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Since the introduction of PERCIST, Siemens Healthcare Molecular Imaging created a PET/CT quantification tool to aid in the adoption of PERCIST evaluation criteria. Using a consistent PET protocol and fixed small region of interest, Siemens’ quantification tool evaluates the most active region of a metabolically active tumor to minimize statistical variability and offer the most consistent results. Siemens supports industry initiatives with this software tool that will make PERCIST data available and reproducible for every patient, so that these criteria will be clinically adopted and used in the field.

RECIST is a well established set of rules for determining response to therapy for patients. These criteria were formed on the basis of measuring anatomical changes in tumors using CT imaging. Because PET/CT imaging can detect changes to the tumor at the molecular level, thought leaders in the molecular imaging field introduced PERCIST criteria to use together with RECIST.

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment. PERCIST criteria allow treatment response to be measured in the absence of anatomic change through the assessment of metabolic activity, often even before anatomical changes take place. The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak SUV within a volume of interest, rather than the common single-pixel measure of SUVmax. The PERCIST quantification tool offers a more robust metric that is less susceptible to statistical variation and noise.

For more information: www.siemens.com/healthcare


Related Content

News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Breast Imaging

May 1, 2024 — After the issuance of updated breast screening recommendations by the U.S. Preventive Services Task Force ...

Time May 01, 2024
arrow
News | Ultrasound Imaging

April 30, 2024 — Best Nomos, a TeamBest Global Company, is launching its most modern, highly innovative Compact SONALIS ...

Time April 30, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Enterprise Imaging

April 25, 2024 — International medical imaging IT and cybersecurity company Sectra has signed two contracts to provide ...

Time April 25, 2024
arrow
Subscribe Now